Avalo Therapeutics Inc. (NASDAQ:AVTX) went down by -11.52% from its latest closing price compared to the recent 1-year high of $4.50. The company’s stock price has collected -11.42% of loss in the last five trading sessions. Press Release reported 12 hours ago that Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Is It Worth Investing in Avalo Therapeutics Inc. (NASDAQ :AVTX) Right Now?
Plus, the 36-month beta value for AVTX is at 1.48. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Avalo Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.50. AVTX currently public float of 95.25M and currently shorts hold a 2.79% ratio of that float. Today, the average trading volume of AVTX was 548.40K shares.
AVTX’s Market Performance
AVTX stocks went down by -11.42% for the week, with a monthly drop of -10.80% and a quarterly performance of -28.09%, while its annual performance rate touched -7.58%. The volatility ratio for the week stands at 5.78% while the volatility levels for the past 30 days are set at 5.68% for Avalo Therapeutics Inc.. The simple moving average for the period of the last 20 days is -21.23% for AVTX stocks with a simple moving average of -24.35% for the last 200 days.
AVTX Trading at -21.88% from the 50-Day Moving Average
After a stumble in the market that brought AVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.67% of loss for the given period.
Volatility was left at 5.68%, however, over the last 30 days, the volatility rate increased by 5.78%, as shares sank -21.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.25% lower at present.
During the last 5 trading sessions, AVTX fell by -19.41%, which changed the moving average for the period of 200-days by -12.70% in comparison to the 20-day moving average, which settled at $2.85. In addition, Avalo Therapeutics Inc. saw -3.03% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AVTX
Current profitability levels for the company are sitting at:
- -706.02 for the present operating margin
- +69.53 for the gross margin
The net margin for Avalo Therapeutics Inc. stands at -961.15. The total capital return value is set at -188.09, while invested capital returns managed to touch -259.05. Equity return is now at value -260.90, with -133.50 for asset returns.
Based on Avalo Therapeutics Inc. (AVTX), the company’s capital structure generated 14.11 points at debt to equity in total, while total debt to capital is 12.36. Total debt to assets is 7.92, with long-term debt to equity ratio resting at 12.37. Finally, the long-term debt to capital ratio is 10.84.
When we switch over and look at the enterprise to sales, we see a ratio of 23.97, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 1.39 and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.